The FDA warned healthcare professionals about six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta (exenatide), indicated for Type 2 diabetes. Amylin and Eli Lilly & Co., joint manufacturers of Byetta, will make labeling changes featuring more prominent warnings about the risk of acute hemorrhagic or necrotizing pancreatitis.
Product news
The FDA warned healthcare professionals about six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta (exenatide), indicated for Type 2 diabetes.